We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+4.22%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.22B
AUM Growth
+$986M
Cap. Flow
+$1.27B
Cap. Flow %
17.6%
Top 10 Hldgs %
44.55%
Holding
109
New
17
Increased
12
Reduced
6
Closed
14

Top Buys

Rank Stock Value
1
CLYM
Climb Bio
CLYM
+$272M
2
CTKB icon
Cytek Biosciences
CTKB
+$226M
3
IVVD icon
Invivyd
IVVD
+$198M
4
ICVX
Icosavax, Inc. Common Stock
ICVX
+$196M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$177M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$112M
2
NVAX icon
Novavax
NVAX
+$102M
3
CRIS icon
Curis
CRIS
+$57.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$56.4M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$51.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEGN icon
101
Legend Biotech
LEGN
$3.7B
– –
-977,503
Closed -$40.1M
MCRB icon
102
Seres Therapeutics
MCRB
$52.2M
– –
-255,277
Closed -$1.9M
NTLA icon
103
Intellia Therapeutics
NTLA
$1.57B
– –
-15,000
Closed -$2.43M
ORIC icon
104
Oric Pharmaceuticals
ORIC
$1.41B
– –
-584,000
Closed -$10.3M
TXMD icon
105
TherapeuticsMD
TXMD
$23.7M
– –
-156,250
Closed -$9.3M
CERE
106
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-2,200,000
Closed -$56.4M
ARYD
107
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
– –
-1,000,000
Closed -$10.7M
TRIL
108
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-5,290,481
Closed -$51.3M
CEREW
109
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
– –
-233,333
Closed -$3.36M
1 2 3 4
5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, RA Capital Management held 109 positions worth $7.22B, up 16% from $6.23B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management deployed $1.27B of net new capital in Q3 2021, opening 17 new positions and adding to 12 existing holdings. Its largest new stake was Climb Bio: 13,150,849 shares worth $236M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Novavax, an estimated $102M trimmed.

  • RA Capital Management's largest Q3 2021 buy was Climb Bio: 13,150,849 shares worth $236M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q3 2021, an estimated $79.6M increase.
  • RA Capital Management's biggest Q3 2021 reduction was Novavax, cutting an estimated $102M.
  • RA Capital Management fully exited Axsome Therapeutics in Q3 2021, selling an estimated $112M.
  • RA Capital Management's ten largest holdings make up 45% of its $7.22B portfolio in Q3 2021.
  • RA Capital Management opened 17 new positions and closed 14 in Q3 2021.
  • RA Capital Management's portfolio value rose 16% quarter-over-quarter to $7.22B.

Based on RA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.